NKX2-1 and lung adenocarcinoma: In particular, we identified the subset of NKX2-1 upregulated presumptive direct targets whose expression was significantly higher (by two-class SAM analysis) in TCGA lung adenocarcinomas with NKX2-1 amplification/overexpression (n = 20), compared to adenocarcinomas without amplification (but still expressing NKX2-1 in a non-amplified context) (n = 60) (Table 1).